Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert Laplanche"'
Autor:
Robert Laplanche, Francis L. S. Tse
Publikováno v:
Pharmaceutical Research. 15:1614-1620
Purpose. SDZ ENA 713 (rivastigmine) is an acetylcholinesterase inhibitor intended for therapeutic use in Alzheimer's disease. The present study compared the pharmacokinetics of [14C]SDZ ENA 713 after intravenous, oral, and dermal administration to ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6272d8327cc3b240fc5cc75b3bf7e4e2
https://doi.org/10.1023/a:1011919603822
https://doi.org/10.1023/a:1011919603822
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 34(3)
Everolimus is a novel macrolide immunosuppressant developed for the prophylaxis of allogeneic renal or cardiac transplant rejection. Treatments with immunosuppressants are often associated with organ toxicity that is linked to high organ exposure. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d41fa638e1dddbcbb6a26fe2828fe1c2
https://pubmed.ncbi.nlm.nih.gov/17431753
https://pubmed.ncbi.nlm.nih.gov/17431753
Autor:
Linda C. Mancione, Dennis E. Schmidt, Robert Laplanche, Ronald J. Polinsky, Peter T. Loosen, Benjamin W. Johnson, John S. Kennedy, Albert Enz, Michael H. Ebert, Winston C. V. Parris
Publikováno v:
Journal of clinical psychopharmacology. 19(6)
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Swit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::425c170c47da69e5a5d6ebad81039cc5
https://pubmed.ncbi.nlm.nih.gov/10587286
https://pubmed.ncbi.nlm.nih.gov/10587286
Autor:
Erich Nüesch, Jean-Louis Steimer, Jean-Philippe Jais, Werner Niederberger, Robert Laplanche, Bernard Fertil
Publikováno v:
Clinical pharmacology and therapeutics. 50(1)
Drug level monitoring during routine clinical visits in the course of phase III trials provides a means to document pharmacokinetic variability in a patient population. Such a pharmacokinetic screen was performed for the new calcium antagonist isradi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::380e1dc6c694b88dbe18775867eaeec3
https://pubmed.ncbi.nlm.nih.gov/1830252
https://pubmed.ncbi.nlm.nih.gov/1830252
Autor:
Robert Laplanche, André L. Blum, Jean-Claude Gfeller, Norman Mazer, Eva Abisch, Mercedes Cucala, Marianne Lukachich, P. Bauerfeind
Publikováno v:
Journal of pharmaceutical sciences. 77(8)
From measurements of drug levels in both gastric juice and plasma, we investigated whether or not a prolonged gastric residence time (GRT) is responsible for the slow absorption kinetics of a "floating" modified-release (MR) capsule of isradipine [is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b5ca5bbbf23caf2169cd28097fafe3
https://pubmed.ncbi.nlm.nih.gov/2974884
https://pubmed.ncbi.nlm.nih.gov/2974884